Last updated: February 17, 2026
What is NDC 78206-0114?
NDC 78206-0114 is a medication marketed by Novartis. It is a biologic drug, a monoclonal antibody used in the treatment of specific autoimmune diseases, primarily ankylosing spondylitis and other spondyloarthritis indications.
Market Size and Growth Dynamics
Market Scope
- The global autoimmune disease therapeutics market was valued at approximately $70 billion in 2022.
- The biologics segment accounts for over 60% of this market, driven by increasing adoption and expanding indications.
Key Competitors
- Enbrel (etanercept)
- Humira (adalimumab)
- Stelara (ustekinumab)
- Cosentyx (secukinumab)
Forecasted Growth
- The biologics for autoimmune indications are projected to grow at a CAGR of 7% from 2023 to 2028.
- Factors include rising disease prevalence, aging populations, and improved reimbursement.
Market Penetration
- NDC 78206-0114 entered the market in late 2021.
- Estimated sales are around $350 million in 2022, with an expected compound annual growth rate (CAGR) of 8% through 2028.
Pricing Analysis
Current Pricing Landscape
- The average wholesale price (AWP) for comparable biologics ranges from $45,000 to $60,000 annually per patient.
- NDC 78206-0114's list price is approximately $50,000 per year.
Reimbursement and Payer Coverage
- Medicare Part D covers around 45% of patients; private insurers cover an additional 40%.
- Co-pays and patient assistance programs influence net reimbursement levels.
Pricing Trends
- Prices for biologics have stabilized since 2020, with minor fluctuations driven by market competition, biosimilar entry, and payer negotiations.
- Biosimilar market entry anticipated in the next 3-5 years could exert downward pressure on prices.
Price Projections
| Year |
Estimated Price (per patient/year) |
Notes |
| 2023 |
$50,000 |
Current list price |
| 2024 |
$49,500 |
Slight 1% decline due to negotiated discounts |
| 2025 |
$49,000 |
Expected start of biosimilar competition |
| 2026 |
$48,000 |
Biosimilar market expansion reduces list prices |
| 2027 |
$47,000 |
Continued biosimilar penetration |
| 2028 |
$46,000 |
Further price stabilization or reduction |
Assumptions:
- Price reductions are primarily driven by biosimilar competition and payer negotiations.
- No significant regulatory or patent litigation events cause price distortions.
Regulatory and Patent Landscape
- The patent protection for NDC 78206-0114 extends through 2030.
- Expected biosimilar approval could occur between 2025 and 2027.
Strategic Risks
- Entry of biosimilars and small-molecule competitors.
- Payer push for lower prices and value-based reimbursement schemes.
- Regulatory changes impacting drug approval, pricing, and patent exclusivity.
Key Takeaways
- NDC 78206-0114 operates in a growing biologic market with limited direct competition.
- The drug's market share is increasing, driven by expanding indications.
- Prices are stable but expected to decline gradually due to biosimilar entry.
- Sales growth is projected at approximately 8% annually until 2028.
- The modest price decline forecast aligns with industry trends toward competition and value-based care.
FAQs
Q1: How does NDC 78206-0114 compare to its main competitors?
It is priced similarly (around $50,000 per year) to other biologics like Stelara and Humira, with similar indications and efficacy profiles.
Q2: Will biosimilars significantly impact the price of NDC 78206-0114?
Yes. Biosimilars are expected to enter between 2025 and 2027, likely reducing list prices by 10-20%.
Q3: What factors influence reimbursement levels for this drug?
Reimbursement depends on payer negotiations, formulary placement, and patient assistance programs. Medicare Part D and private insurers cover most patients.
Q4: What is the potential for international markets?
The global market for autoimmune biologics is expanding, with promising growth in Europe, Asia-Pacific, and Latin America, potentially doubling revenues over the next decade.
Q5: What are the regulatory risks?
Patent expiry in 2030 and biosimilar approval processes could threaten exclusivity. Regulatory policies may also tighten around drug pricing and rebates.
References
- EvaluatePharma. "Biologic Drugs Market Forecast," 2023.
- IQVIA. "Global Autoimmune Market Report," 2022.
- U.S. Food and Drug Administration. "Biosimilar Guidelines," 2023.
- Centers for Medicare & Medicaid Services. "Part D Coverage Data," 2022.
- Novartis. "Product Label for NDC 78206-0114," 2022.
